

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**





(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 781 565 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:  
02.07.1997 Bulletin 1997/27

(51) Int. Cl.<sup>6</sup>: A61L 29/00, A61L 31/00,  
C08L 67/02

(21) Application number: 95120739.8

(22) Date of filing: 29.12.1995

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE

(71) Applicant: DENCO, INC.  
Wilmington, Delaware 19899-2207 (US)

(72) Inventor: Spencer, Dudley W.C.  
Wilmington DE 19809 (US)

(74) Representative: Wagner, Karl H., Dipl.-Ing. et al  
WAGNER & GEYER  
Patentanwälte  
Gewürzmühlstrasse 5  
80538 München (DE)

(54) **Ionomeric modified poly-ether-ester plastic tube for use in conveying medical solutions and the like**

(57) An ionomeric modified poly-ether-ester plastic material is used as a substitute for the conventional uses of polyvinyl chloride in such applications as tubing for medical applications, for bags and other medical containers, for tubing in food processing and as sheets and films for bacterial and virus exclusion. The ionomeric modified poly-ether-ester has various advantages which make it particularly suitable for such uses.

EP 0 781 565 A1

**Description****Background of the Invention**

5 Polyvinylchloride (PVC) is the accepted material for use as tubing in various medical applications, such as peritoneal dialysis, blood processing, chemotherapy and other uses. In such uses, a consumable is conveyed through the tubing from one location to another. For peritoneal dialysis (CAPD), for example, it is also the practice to replace a used dialysate bag with a new bag. This is accomplished by cutting through the PVC tubing leading from the used bag and then welding tubing from a new bag to the cut portion of the tubing so that one bag may replace another. PVC is also  
10 the generally accepted material for forming bags and other medical containers and is commonly used as tubing in food processing particularly for fluids and semi-solids. In addition, PVC is the material generally used for forming sheets and films for bacterial and virus exclusion. Despite its acceptance by the art, PVC has a number of disadvantages which would be desirable to overcome in such uses. For example, conventional PVC includes a plasticizer (DOP) which might leach into the solutions in the bag. Further, after PVC has leached its DOP, large volumes of PVC particulates are  
15 released. Other disadvantages will be later referred to.

**Summary of the Invention**

20 An object of this invention is to provide a material which will act as an improved replacement for PVC in the conventional uses of PVC.

A further object of this invention is to provide such a material which can be used as tubing for medical applications, as bags and other medical containers, for tubing food processing and as sheets and films for bacterial and virus exclusion.

25 In accordance with this invention the material which meets the above objects is an ionomer modified poly-ether-ester. The ionomer modifier is added in a range of 1% to 20% depending upon the end use requirement.

**The Drawings:**

30 Figure 1 is a perspective view of a tube made from ionomer modified poly-ether-ester in accordance with this invention;

Figure 2 is a schematic view of a urinary drainage system utilizing the tubing of Figure 1;

Figure 2A is an enlarged cross-sectional view of a top air seal shown in the corresponding circled portion of Figure 2;

35 Figure 2B is an enlarged cross-sectional view of a discharge line in the corresponding circled portion of Figure 2;

Figures 3-4 are graphs comparing the elongation and strength characteristics of PVC welded to the material of this invention (Figure 3) and of the ionomer modified poly-ether-ester of this invention alone (Figure 4);

Figure 5 is a schematic view of a prior art system for steam sterilizing when using PVC tubing in peritoneal dialysis;

Figure 6 is a schematic view showing a sterile solution fed to sterile bags using the ionomer modified poly-ether-ester of this invention;

40 Figure 7 is a schematic view showing a primary blood bag and four satellite bags connected by the tubing of this invention as used in blood processing;

Figure 8 is a schematic view showing prior art chemotherapy treatment using PVC tubing;

Figure 9 is a view similar to Figure 8 showing use of the tubing of this invention; and

Figure 10 is a schematic view showing parenteral feeding of the body using the tubing of this invention.

45

**Detailed Description**

The present invention is directed to providing a material which can be used as a substitute for PVC in the conventional uses of PVC while having advantages over such PVC material. The material of this invention is an ionomer modified poly-ether-ester. Poly-ether-ester is a well known material generally used to take advantage of its high strength characteristics. Such material is used, for example, in clothing generally referred to as polyester clothing. Ordinarily, the strength of such material would make it unsuitable for use as a substitute for PVC in the uses of PVC with which this invention deals. It has been discovered, however, that the poly-ether-ester material can be modified by incorporation of a small amount of an ionomer which would modify the characteristics of the poly-ether-ester by giving it sufficient frigility to, for example, permit the material when used as a sealed tube to pop open. The specific amount of ionomer would depend upon the end use.

In general, the ionomer modifier comprises from 0.5-50% and preferably from 1% to 25% of the combination depending upon the end use requirement. For example, in tubing such as for CAPD use where the material is to be sealed, welded and the lumen reopened the broad ionomer composition range would be 2% to 15%, a more preferred

range of 3% - 10%. A range of 7-10% is ideal. The result is a tube which is strong, sufficiently rubber like, and a degree of fracture to make reopening of the sealed tubes by finger pressure. For bags, films and other thin structures the ionomer would be present in a range of from 1% to 50% of the combination depending on the end use requirements. For food processing tubes and aseptic surgical draping procedures a range of 10% to 20% is desirable. For implanted catheters and sutures the range of 0.5 to 1% is preferred.

5 The material of this invention is thus an ionomeric modified poly-ether-ester wherein the material has from 1% to 25% ionomer and from 99% to 75% poly-ether-ester with mixtures of 50-50% being feasible. The basic material components are as follows:

10 Poly-ether-ester

POLY-ETHER-ESTER BLOCK COPOLYMER (Block poly-ether-ester) (Co-poly-ether-ester) (Polyester elastomer) (Thermoplastic poly-ether-ester) Tradenames: Hytrel, Lomod, Pelprene and others. A block copolymer containing both polyether and ester blocks. The best known example is poly-(tetramethyleneterephthalate-b-poly-oxytetramethylene-terephthalate).

15 Ionomer

IONOMER Trade name Surlyn, among others. A copolymer of ethylene with 1-10% methacrylic acid, which has 20 been converted to methacrylate salt, often the sodium, magnesium or zinc salt, by neutralization with the appropriate base. The resultant ionic groups tend to aggregate to form domains which act as physical crosslinks for the polyethylene. However, the domains break down on heating, so the material may be melt processed as other thermoplastics. The copolymers are produced by the high pressure ethylene polymerization process and so are similar to low density polyethylene. The comonomer decreases crystallinity but consequent loss of stiffness is restored by the physical 25 crosslinks. The material is more transparent than LDPE and shows better adhesion, which makes it useful as a layer in laminated coextruded packaging films and in, therefore, homogenous mixing.

30

35

40

45

50

55

## EP 0 781 565 A1

Material Properties

## Poly-ether-este

5	Property	ASTM Test	Units	Typical
10	Hardness, Durometer D	D 2240	points	30
10	Hardness, Durometer A	D 2240	points	85
<b>Processing</b>				
15	Melt Flow Rate at 190°C (374°F)/2.16 g load	D 1238	g/10 min	5
15	Melting Point	D 3418 <sup>b</sup>		
20	Peak of Endotherm		°C(F)	170 (338)
20	Extrapolated End Point		°C(°F)	200 (392)
<b>Stress/Strain</b>				
25	Tensile Strength	D 638 <sup>c</sup>	MPa(psi)	26.2 (3800)
25	Elongation at Break		%	700
30	Stress at 5% Strain		MPa(psi)	1.3 (190)
30	Stress at 10% Strain		MPa(psi)	2.1 (300)
35	Stress at 15% Strain		MPa(psi)	2.6 (380)
<b>Stiffness</b>				
40	Flexural Modulus:	D 790 <sup>d</sup>		
40	at -40°C(-40°F)		MPa(psi)	145 (21,000)
40	at 23°C (73°F)		MPa(psi)	28 (4,060)
40	at 100°C (212°F)		MPa(psi)	14 (2,030)
45	Brittleness Temperature, Solenoid	D 746	°C(°F)	<-150 (<-157)
<b>Toughness</b>				
50	Initial Tear Resistance, Die C	D 1004 <sup>e</sup>	kN/m (lb f/in)	77 (440)
50	Resistance to Flex Cut Growth, Ross(pierced)	D 1052	cycles to 5x cut growth	>1 x 10 <sup>6</sup>
55	Izod Impact (Notched)	D 256f		
55	at -40°C(-40°F)		J/m (ft • lb f/in)	No Break
55	at 23°C (73°F)		J/m (ft • lb f/in)	No Break
<b>Abrasion Resistance</b>				
55	Taber, CS-17 wheel, 1 kg load	D 1044	mg/1,000 cycles	2
55	Taber, H-18 wheel, 1 kg load	D 1044	mg/1,000 cycles	90
<b>Miscellaneous</b>				
60	Compression set, after 22h at 70°C (158°F) 2.8MPa (400psi) load	D 395 <sup>g</sup>	%	16
60	Specific Gravity	D 792	-	1.07
60	Water Absorption (24 h)	D 570	%	3
60	Softening Point, Vicat	D 1525 <sup>h</sup>	°C(°F)	83 (181)
60	Heat Deflection Temperature 0.5 MPa (66 psi)	D 648	°C(°F)	46 (115)

Ionomer

5	Film Property (2 mil blown, 3:1 BUR)	Typical Value	Test Method
10	Ultimate Tensile Strength, MD/TD, psi (MPa)	4900 (33.8)/ 5900 (40.7)	ASTM D-882
15	Ultimate Elongation MD/TD, %	350/400	ASTM D-882
20	Secant Modulus, MD/TD, psi (MPa)	35,000 (241)/ 38,000 (262)	ASTM D-882
25	Spencer Impact Strength, in lb/mil (J/mm)	7.0 (31)	ASTM D-3420
30	Dart Drop Strength, g/ml (g/μm)	300 (11.8)	ASTM D-1709 Method B
35	Elmendorf Tear Strength, MD/TD, g/mil (mN/μm)	18 (6.9)/ 19 (7.3)	ASTM D-1922
40	Gloss, 20°	75	ASTM D-2457
45	% Haze	3.0	ASTM D-1003

Resin Property	Typical Value	Test Method
Melt flow index, dg/min	1.3	ASTM D-1238 condition 190/2.16
Melt Point, °C (°F)	98 (208)	ASTM D-3418
Freeze Point, °C (°F)	68 (154)	ASTM D-3418
Vicat softening point, °C (°F) Ion type	74 (165) Sodium	ASTM D-1525 —

35 Poly-ether-esters are valuable materials because they have excellent low temperature properties (freezing) and are impervious to chemicals, oils and tissue. They have one serious negative, however, for many end-uses: They stretch 7x their length under low stress. For example, a tube one foot long will stretch to seven feet before breaking. Industrial goods such as bags, films, tubes, etc. readily warp out of shape and become unacceptable as end-use products. The present invention adds an ionomer to the composition to make useful, thin products.

40 Ionomers are somewhat like polyethylene in that they are useful as films because they are excellent for food wrapping, medical and pharmaceutical packing and are impervious to most oils and chemicals. Like polyethylene, they puncture readily and only stretch 3x before fracture.

45 A common use is a coating over stronger materials and are frequently used as a co-extrusions on nylon and other films to provide heat sealing.

The invention makes use of the fact that both poly-ester-ethers and ionomers melt at the same temperature. (191°C) Instead of a coating, the invention mixes them together. In this way, the negatives of the two materials could be adjusted in a variety of ways to make new materials that are stronger than the ionomers, and less stretchy than the poly-ether-esters.

50 Combining the two materials as described also reduces another major limitation of the poly-ester-ethers (P.E.E.). They can absorb excessive moisture depending upon temperature and humidity. In the case of P.E.E. use in autoclaved (steam sterilized) medical tubing for example, the moisture pick-up makes the tubing unacceptable for further processing. Adding 5% to 7% ionomer to the composition reduces the moisture absorbance to less than 1% by weight. A level comparable to medical grade PVC and well within the limits required for TCD® to welding.

55 For forming the material of this invention the following process may be used. The two materials are fed separately in pellet form into a single screw extruder. A twin screw extruder could be used satisfactorily but a single screw is sufficient and simpler to control. The two pellet streams are mixed to the required ratios and fed into the extruder. Extrusion rates of 10 to 250 lbs per hour are practical at melt temperatures of 180°C to 200°C, with 191°C being ideal. The melt is fed through a sizing die and liquid quenched as it exists the die for accuracy and handling purposes.

A typical extruder heating and mixing profile would involve feeding the ionomeric and P.E.E. pellets from individual feed hoppers into the extruder where the feed zone of the extruder is at 300°F. The material would then pass to a compression zone at 350°F. The materials would then pass into a melting zone at 375°F. Finally, the material would be

extruded into the desired shapes. Techniques such as conventionally used for PVC could then be used for forming the end products.

Figure 1 illustrates a tube 10 made from an ionomer-modified poly-ether-ester in accordance with this invention. Tube 10 has characteristics which make it ideally suited for its intended uses as an improved replacement for PVC. For example, using a modification ratio of 3% to 10%, the material will provide seal strengths in excess of 60 psi internal pressure as indicated in Table 1. The material will weld to itself with tensile strengths of 10 kgs for tubes of 5.4 mm outside diameter and a wall thickness of 0.7 mm as indicated in Figure 4. Such tensile strengths can even exceed 10 kgs.

The welds for tube 10 can be reopened with the same ease as PVC by external finger pressure such as by squeezing.

There is no degradation such as the smoke or particulates characteristic of the PVC with the material of this invention being generated at welding temperatures of 320°C and exposure times of less than 1 second. The ionomer-modified poly-ether-ester of this invention can be steam or ETO sterilized without geometry changes. In particular the material will permit steam sterilization of itself and the tube contents without changing the sealing or welding conditions because of extremely low water (steam) adsorption or retention.

Figures 2, 2A and 2B illustrate use of this invention for urinary drainage application. As shown therein tubing 10 is 5% ionomer-modified and is utilized as the tubing which leads from an operative site, such as the patient 12 to a urinary bag 14. Urinary bag 14 may also be made of the ionomer-modified poly-ether-ester of this invention. In use for urinary drainage application the invention has advantages over medical grade (Class VI) di-octyl-phthalate (DOP) plasticized PVC. For example, since there is no plasticizer with the material of this invention there is no leaching of plasticizer into the 20 bag solutions as is common with PVC. Additionally, after PVC has leached its DOP, large volumes of PVC particulates are released. This does not happen with the material of this invention.

For urinary drainage application the full bag 14 is to be separated from the patient discharge line so that it can be replaced by a fresh bag. A preferred practice of accomplishing such substitution would be to use the total containment sterile connection device as described in U.S. Patent Nos. 5,141,592; 5,156,701; 5,158,630; 5,209,800; 5,244,522 and 25 5,279,685 the details of which are incorporated herein by reference thereto. Such sterile connection device is referred to as TCD®. By using such techniques the discharge line is disconnected at any suitable location such as the location 16. This leaves a portion of the tubing extending from the operative site or patient 12. A new bag 14 is attached by welding a tubing 10 leading from the new bag so that the tube sections become integral at the weld connection at location 16. The full or used bag is completely sealed and set aside to be weighed for total volume and volume per unit time for 30 determining the discharge rate. The sealing is advantageously accomplished because of the sealing characteristics of the ionomer-modified poly-ether-ester. Figure 2A, for example, shows a seal 18 formed at the top of bag 14 and Figure 2B shows a seal 20 formed at the discharge line of bag 14 by use of TCD®.

The full bag 14 and its contents can be disposed of as a sealed biological waste. Alternatively, the bag 14 can be suspended on a standard bag holding pole over a commode and the bottom seal 20 can be opened by use of the fingers and thumb as is possible from seals formed by the total containment sterile discharge connection use for PVC. The bag contents will not drain at this point because of lack of air displacement. When the top seal 18 is opened again by the total containment device have the advantage of draining the bag contents without tools and in the manner that the bag contents do not contact the nurse's hands. This feature is of extreme importance to protect the nurses from contamination and also prevents cross-contamination with a hospital ICU facility. Cross-contamination in ICUs is currently 40 a major problem.

The new or empty and sterile bag 14 is welded to the patient line at welding site 16 immediately after removing the full bag to provide uninterrupted flow from the patient.

The following represents an experiment to compare the ionomer-modified poly-ether-ester designated in the 45 experiment as E77-200-7-3 as a substitute for PVC tubing. The E77-200-7-3 was made from a blend of 90% Hytrel poly-ether-ester and 10% Surlyn ionomer. The poly-ether-ester had a hardness of Durometer 30 on the D scale and a melt flow rate of 5 grams/10 minutes. The ionomer had a hardness of Durometer 60 on the D scale and a melt flow rate of 1.3 grams/10 minutes.

##### 50 Experimental plan:

###### PART A: (Disconnect Seal Test)

- 55 1) Cut the tubing (E77-200-7-3) into 25 samples 6 inches long.
- 2) Place each sample in the TCD™ and perform a disconnect. This will cut the tube sample in half and seal both ends producing 50 sealed pieces of tubing
- 3) Place each piece of tubing onto the pressure tester and pump up to 60 psi. If the tubing maintains that pressure for 1 minute then it passes.
- 4) Place the seal of each piece of tubing in the Arbor Press and squeeze the seal 5 times.

## EP 0 781 565 A1

- 5) Remove the tubing from the press and see if the seal has broken open.
- 6) Repeat steps 4 & 5, 20 times or until the seal breaks, whichever occurs first.
- 7) Repeat step 3.

### 5 PART B: (PVC Disconnect Seal Test)

- 1) Repeat Part A using 5 samples of PVC tubing.

### 10 PART C: (Connect Test)

- 1) Place two of the disconnect pieces of tubing from PART A into the TCD™ and perform a connect.
- 2) Record whether the tubing can be popped open or not.
- 3) Repeat steps 1 & 2 using all 50 pieces, thus producing 25 samples 6 inches long.

### 15 PART D: (Welded Flow Test)

- 1) Using a metal can that has a tubing connector at its base, attach one of the welded 6 inch samples to the can.
- 2) Fill the can with 2 cups of water and record the amount of time required for the can to drain through the tubing. Make sure that the draining water is caught in another can so that the same amount of water can be used in all the tests.
- 3) Repeat step 2 with eight more welded tube samples and one non-welded tube sample.

### PART E: (Weld Tensile Strength Test)

- 25) 1) Load and run the Tensile Instrument program "INSTFIXE.BAS". This program will save to disk the tensile strength curve results for each of the samples, so they can be regenerated using the program "EXCEL".
- 2) Calibrate the Tensile Instrument.
- 3) Place one of the welded samples into the clamps of the Tensile instrument and start the test.
- 4) Stop the test when the lower clamp of the Tensile Instrument reaches the automatic stop switch.
- 30) 5) Save the results to disk.
- 6) Repeat the steps 3, 4 & 5 with the remaining 24 samples and one non-welded tubing.

### PART F: (Weld Tubing to PVC Tubing)

- 35) 1) Set the TCD™ to the CONNECT mode.
- 2) Place one 3 inch piece of Tubing (E77-200-7-3) into one of the TCD™ clamps.
- 3) Place one 3 inch piece of PVC Tubing into the other TCD™ clamp.
- 4) Perform the connect operation so that the E77-200-7-3 tubing and the PVC tubing are welded together.
- 40) 5) Remove the tubing from the TCD™ and record whether the weld can be popped open,
- 6) Place the E77-200-7-3-PVC tubing in the Tensile instrument and repeat steps 1-5 of PART E.

45

50

55

Observations and Data:

Table 1

5

## PART A: (Disconnect Test)

Sample #	Disconnect Seal Strength of each End		Seal Squeeze Test using Arbor Press	
	1 <sup>st</sup> Half of Tubing	2 <sup>nd</sup> Half of Tubing	1 <sup>st</sup> Half of Tubing	2 <sup>nd</sup> Half of Tubing
1	61 psi *	60 psi *	100 squeezes *	100 squeezes *
2	60 psi *	60 psi *	100 squeezes *	100 squeezes *
3	60 psi *	60 psi *	100 squeezes *	100 squeezes *
4	60 psi *	60 psi *	100 squeezes *	100 squeezes *
5	60 psi *	60 psi *	100 squeezes *	100 squeezes *
6	60 psi *	60 psi *	100 squeezes *	100 squeezes *
7	60 psi *	60 psi *	100 squeezes *	100 squeezes *
8	62 psi *	60 psi *	100 squeezes *	100 squeezes *
9	62 psi *	61 psi *	100 squeezes *	100 squeezes *
10	60 psi *	60 psi *	100 squeezes *	100 squeezes *
11	60 psi *	60 psi *	100 squeezes *	100 squeezes *
12	60 psi *	60 psi *	100 squeezes *	100 squeezes *
13	60 psi *	60 psi *	100 squeezes *	100 squeezes *
14	60 psi *	60 psi *	100 squeezes *	100 squeezes *
15	60 psi *	64 psi *	15 squeezes	100 squeezes *
16	60 psi *	60 psi *	100 squeezes *	100 squeezes *
17	60 psi *	60 psi *	100 squeezes *	100 squeezes *
18	60 psi *	60 psi *	100 squeezes *	100 squeezes *
19	60 psi *	61 psi *	100 squeezes *	25 squeezes
20	60 psi *	60 psi *	100 squeezes *	100 squeezes *
21	62 psi *	60 psi *	100 squeezes *	100 squeezes *
22	60 psi *	60 psi *	100 squeezes *	100 squeezes *
23	60 psi *	63 psi *	100 squeezes *	100 squeezes *
24	60 psi *	60 psi *	100 squeezes *	100 squeezes *
25	61 psi *	60 psi *	100 squeezes *	100 squeezes *

Note: \* indicates the seal did not break or leak.

45

50

55

EP 0 781 565 A1

Table 2

PART B: (PVC Disconnect Test)				
PVC Tubing	Disconnect Seal Strength of each End		Seal Squeeze Test using Arbor Press	
Sample #	1 <sup>st</sup> Half of Tubing	2 <sup>nd</sup> Half of Tubing	1 <sup>st</sup> Half of Tubing	2 <sup>nd</sup> Half of Tubing
1	62 psi *	60 psi *	10 squeezes	10 squeezes
2	60 psi *	60 psi *	15 squeezes	10 squeezes
3	60 psi *	60 psi *	10 squeezes	15 squeezes
4	62 psi *	63 psi *	10 squeezes	10 squeezes
5	60 psi *	60 psi *	20 squeezes	10 squeezes
6	60 psi *	60 psi *	10 squeezes	10 squeezes
7	60 psi *	60 psi *	10 squeezes	15 squeezes
8	62 psi *	60 psi *	5 squeezes	10 squeezes
9	60 psi *	63 psi *	10 squeezes	10 squeezes
10	60 psi *	60 psi *	10 squeezes	10 squeezes

Note: \* indicates the seal did not break or leak.

PART C: (Ability of weld to pop open.)

All 25 connected (welded) Samples (E77-200-7-3) popped open easily

Table 3

PART D: (Effect of Weld on Water Flow through E77-200-7-3 Tubing)					
Sample #	Flow Time (sec)	Flow Time (sec)	Flow Time (sec)	Avg Flow Time (sec)	Flow Change (%)
No Weld	90.74	90.41	90.3	90.48	100%
1	97.97	98.29	98.4	98.22	91.40%
2	101.27	101.6	100.9	101.25	88.10%
3	95.88	95.21	95.28	95.45	94.50%
4	93.51	92.89	93.45	93.28	96.90%
5	104.45	103.52	103.44	103.81	85.20%
6	101.24	100.96	100.26	100.82	88.60%
7	101.62	100.34	100.12	100.69	88.70%
8	98.67	97.81	97.27	97.91	91.80%
9	99.64	99.65	99.48	99.59	89.90%

An advantage of the ionomer-modified poly-ether-ester is its ability to be effectively welded to conventional PVC.

This is important because it permits the replacement of some of the PVC components with the new material. Thus, for example, in CAPD usage it is necessary to remove a used filled bag for replacement by a new empty bag. The conventional PVC tubing could be cut and tubing from the new material could be welded to the remaining PVC tube segment. The new material components could thus gradually replace their PVC counterparts. Figure 3 demonstrates the weld strength of PVC tubing to ionomer-modified poly-ether-ester tubing.

Figures 3 and 4 are graphs illustrating the ability of the weld to pop open. As shown therein with use of the ionomeric modified poly-ether-ester of this invention (Figure 4) the unsealing characteristic is accomplished with approximately the same ease as in PVC tubing welded to the modified poly-ether-ester tubing (Figure 3).

5 Figures 5-6 illustrate use of the invention with respect to peritoneal dialysis (CAPD). Figure 5 represents the prior art practices wherein a tube 22 is utilized made from PVC. In such applications PVC is the material of choice of the health care industry for both the tubing and the solution bags 24. The reasons for favoring PVC are that its long standing use started early in the 1960s. Additionally, there is film clarity for visual clarification and PVC provides low cost and abundant supplies. The PVC used for peritoneal dialysis, however, must undergo bulk sterilization after packaging to insure sterility to the entire product offering prior to patient use. Steam sterilization (250°F for thirty minutes) of PVC in contact with dialysis solutions causes several serious problems. For example, the PVC plasticizer (DI-OCTYL-PHLLATE), DOP, leaches out of the PVC composition during steam sterilization and into the dialysis solution. DOP is under suspicion of being a low level carcinogen. A further product that is after DOP leaching the residual PVC composition is vulnerable to particulates being formed and entering the dialysis solution which in turn enters the patient's body. Further, water adsorption (from the steam sterilization) into the patient tubing and bags reduces the plastic strength by 10 approximately 50% causing bag leakage and sterility failures. Figure 5 illustrates the conventional practice of using PVC as a material for the tubing 22 and bag 24 wherein the solution 26 in the bag 24 is caused to flow through tubing 22 to the patient's site 28. Steam sterilization takes place in chamber 30. Figure 5 also illustrates the separation and connection area 32 used for replacing solution bags by separating and then rejoining the PVC transfusion line 22.

15 20 Figure 6 illustrates use of the ionomeric modified poly-ether-ester for the tube 10 and bag 14. This material overcomes the PVC problems in several ways without sacrificing the positive attributes of PVC. With the material of this invention there is no plasticizer, thus leaching is not a problem. The material also does not form particulates and is 25 impervious to steam sterilization to retain 100% of its strength. The ionomeric modified poly-ether-ester has another positive feature that is unique to sterile connection devices that use a heated blade to achieve sterility. The material does not make smoke. Conversely, when PVC is heated using the TCD™ instrument of the aforesaid patent the plasticizer DOP evolves as fine aerosol droplets that gives the appearance of smoke. Means must be provided therefore to contain and dispose of the smoke harmlessly. Since the poly-ether-ester of this invention has no plasticizer, no smoke is formed using the TCD™ process.

30 35 The use of the total containment device TCD™ has a more significant potential for peritoneal dialysis, however, in that steam sterilization and its problems can be avoided entirely. For example, the ionomeric modified poly-ether-ester consumable bags, tubes, etc. can be bulk sterilized by ethylene oxide at the point of manufacture. The solutions can also be sterilized in bulk storage tanks and made ready to fill the previously sterilized bags. Using the TCD™ the sterile 40 solutions can be fed to the sterile consumable thus avoiding steam sterilization. Figure 6 illustrates by use of the connect/disconnect areas 16 how the ionomeric modified poly-ether-ester of this invention for tubing 10 can be used for replacing bags thereby resulting in a plurality of filled bags 34 with the unfilled bags 36 ready to be connected by weld 45 50 55 16 which would join its tubing 10 to the tubing leading from the sterile solution container 14.

Figure 7 illustrates use of the invention for blood processing. In this application the use of ionomeric modified poly-ether-ester materials has several end-use advantages. Since the material has no plasticizers the problems of plasticizer leaching into the blood are eliminated. The problems of mixing and matching of various sources of blood bags and tubing are also eliminated. Mixing and matching is viewed by the FDA as a health threat when bags and tubing of unknown source and composition are introduced into blood centers because of cost or availability. Eventually the material can be frozen and retain its flexibility, thus avoiding brittle fracture.

Mix and match is considered by the FDA as a serious quality control and safety problem in the blood processing industry. Mix and match is an expression used to describe the chaotic situation in blood banks brought on by economics. Blood banks buy blood bags and tubing strictly on price without too much regard to source. Global dumping practices, questionable polymer compositions and tube size variation all contribute to the problem. In order to exercise a measure of control the FDA would prefer to be able to mandate a set of regulations regarding tube quality and be able somehow to exclude tubing that does not meet the FDA criteria.

The ionomeric modified poly-ether-ester material meets this requirement again because the material does not contain plasticizers. Commonly used medical grade PVC contains up to 40% DOP as a plasticizer that vaporizes to a smoke when the welding temperature exceeds 200°C. By using what amounts to a small smoke detector in the TCD™ the instrument can detect the smoke generation and refuse to complete the welding cycle. Specifically, prior to making a weld the tube ends are made to touch the wafer for one second. If no smoke is generated the process will proceed to make a weld. If smoke is detected the instrument will abort. In this way, the mixture will mix and match problem so important to the FDA and safety of the nation's blood supply can be avoided.

55 Use of the ionomeric modified poly-ether-esters have a positive effect when used in conjunction with TCD™ in that tube sealing (separating) can be accomplished in the TCD as well as connections. Blood banks have the capability of sealing off tubing by radio frequencies (RF) sealers. Because of the radio frequency, however, the equipment is normally located away from the blood processing areas and shielded for safety (booths). The inconvenience of going to a sealer encourages people to make poor seals via hot plates and bunsen flames rather than taking the bags to the RF

5 sealer. Use of the TCD™ avoids this problem. The TCD™ is located in the work place. The use of the TCD™ in blood banking has another important advantage. It is called "un-bundling" and means complete flexibility to disconnect and connect blood bags at will. Without the sterile connection technology afforded by TCD™ this concept is not possible. For example, when blood is collected at the blood banks it is not known at that time what blood fractions will be required to meet end use needs. To overcome this unknown all blood is collected in bag sets. That is, a primary blood bag and four satellite bags are sent as a sterilized set. This is illustrated in Figure 7 wherein the blood supply needle 38 has its tubing 10 leading to primary blood bag 40 with tubing 10 also leading to the four satellite bags 42 each of which has its tubing 10 connected to the main tubing by the TCD™ connect or disconnect location 16.

10 After the blood is centrifuged the fractions are expressed over into various component bags and sealed off. Once sealed off the bags can not be re-entered without compromising sterility. In the practice of this invention all of the tubing 10 and the various bags 40,42 would be made of the ionomer modified poly-ether-ester material.

15 If, for example, only whole blood is needed, the four unused satellite bags 42 are separated and discarded. At approximately \$2.00 per bag this loss is keenly felt by the blood bank. Moreover, if the bags are used and sealed it is not possible to enter the bags to enhance the cell life by the addition of stabilizers, nutrients or enhancers without compromising sterility.

20 The use of the TCD™ has made "un-bundling" possible. The TCD™ is designed to steriley disconnect and connect sterile containers at will thereby providing the medical profession a desired level of flexibility and at lower consumable costs.

25 The use of the ionomer modified poly-ether-ester materials has proven to be non-pyrogenic to human tissue through wide spread use of permanently placed interval sutures. For this reason, the poly-ether-ester material is approved by the FDA for internal human use and is ideal for blood bags.

30 Figures 8-9 relate to use of the invention for chemotherapy. Figure 8 illustrates the conventional practice to administer chemo-therapeutic drugs for cancer patients by introducing the drugs via syringe 44 or a pump into the intravenous transfer tubing 22. Solution would also flow into PVC tubing 22 from PVC bag 24. The syringe port is a convenient entry site for bacteria. For patients whose immune system is depressed from the therapy bacteria entry is life threatening. This problem can be eliminated by the use of the TCD™ instrument.

35 Use of the TCD™ instrument in combination with the ionomer modified poly-ether-ester material for chemotherapy application has several end use advantages. Since there is no plasticizers involved, the danger of plasticizer leaching into the patient is eliminated. Since there are no particulates this form of contamination into the patient's blood stream is also eliminated. The poly-ether-esters are already used widely within humans for sutures and arterial repair. They present no pyro-geneic defects therefore for human use.

40 Figure 9 illustrates use of ionomer modified poly-ether-ester material for bag 14 and tubing 10. As shown therein at the normal entry port location 46 a ionomer modified poly-ether ester tube 48 is spliced into the line 50 also made of ionomer modified poly-ether-ester and is terminated with a closed (sealed) distal end 52. The syringe 44 or pump is steriley enclosed in a sheath 54 and terminated with a closed sealed distal end.

45 Making a sterile connection via the TCD™ the connection is totally contained. No bio-burden can enter the patient and no chemotherapy agents can escape outside the system. The syringe can also be steriley disconnected by the TCD™ when the procedure is complete.

50 Figure 10 illustrates use of the invention for parenteral feeding. For cancer patients who have suffered alimentary tract removal because of the cancer, feeding is accomplished by liquid nutrients fed into the patient's blood stream by way of a tube inserted into a sub-clavian vein and then into the heart.

55 Long term implantation of PVC tubing is also a problem. PVC plasticizer extraction directly into a patient's blood stream is particularly troublesome.

60 As pointed out in Biocompatible Polymers, Metals and Composites by M. Szycher, Sponsored by Society of Plastics Engineers Inc., Techmomic Publishing Co. 1983, flexible PVC compounds can contain up to 40% plasticizer. While the chosen material is very carefully selected for its high purity and low toxicity, it can be extracted from PVC by contact with some fatty substances, such as by blood or the digestive system. When contact times are short there is no difficulty, but for a number of applications in which PVC may be in contact with the patient's system for longer periods extraction of plasticizer is much less acceptable. Striffening of PVC due to plasticizer being extracted may cause patient's considerable discomfort when a feeding or wound drainage tube is removed after prolonged use. Blood stored in PVC bags or flowing through PVC tubes for long periods will also extract plasticizer. While that most commonly used, DEHP, has been shown to be of low toxicity it is naturally desirable to avoid any extra burden on a patient's system. This is obviously more important for those needing regular hemodialysis for blood transfusions.

65 The use of ionomer modified poly-ether-ester materials for tubing is beneficial in two ways. There is no leaching of plasticizers into the patient's system from the implanted tube. Additionally, the poly-ether-ester material is compatible with the TCD™ for making sterile connects and disconnects from the implant. Figure 10, for example, illustrates the use of a poly-ether-ester bag 14 supplying the liquid nutrients through poly-ether-ester tubing 10 into the patient's heart 56. By use of the TCD™ a sterile connect/disconnect procedure 16 can be effectively used to replace the bag 14 with a new bag 14.

The invention may also be used for cell culturing and particularly has applications in connection with the TCD™ in biotechnology. In such applications the ionomer modified poly-ether-ester would be used as tubing from the reactor.

5 Biotechnology is a rapidly growing business area with R&D expenditures of \$2BLN in 1994 (U.S.). TCD™ technology can fill unmet needs for improved connections in several segments of this market. The value-in-use is a \$2-10/connection with a total market opportunity of \$28MM (1990) and estimated to grow to \$78MM (1995). Mammalian cell fermentation is targeted as the market entry segment for the TCD™ technology.

10 The biotechnology business utilizes many techniques developed by molecular and cellular biologists in the 1980's for increasing the production of a specific protein in a cell by redesigning, or engineering, its DNA. This business area produced high value proteins which are used in diagnosis or therapy of diseases as well as cost reducing processes in energy conversion and agriculture processes. The common factors in all biotechnology segments are the creation and isolation of a unique cell type and then the growth of this cell to isolate product(s).

15 Cell growth occurs in a steriley isolated system which provides nutrients and removes waste products, a process called fermentation. To maximize product yield, this fermentation system must also prevent the entry of other "non-unique" cells which would grow and contaminate the system.

20 The technology to produce and isolate unique cells is well developed, although it requires highly skilled personnel. Unique cells may be created from either bacteria or cells isolated from more complex organisms, including humans. The technology to grow large quantities of bacterial cells is well established. Cells from complex organisms, called mammalian cells, grow more slowly than bacterial cells and require more complex nutrients. the development of new ways to grow these unique mammalian cells in large quantities is one of the major problems in biotechnology today.

25 Preventing non-unique cells from entering the fermentation system is important for all types of cells. In bacterial systems contamination is not as significant because of the design of fermentors and the length of the fermentation process, a few days. A typical mammalian cell fermentation cycle is three weeks long but the nutrients and wastes are exchanged several times a day. Accidentally introducing bacterial contamination when exchanging the fluids is a real possibility. Such contamination destroys the mammalian cells in several days.

30 Presently about 90% of the products produced by biotechnology are grown in bacterial cells lines. However, research is focusing more on producing unique cells from mammalian cells because some proteins can be produced more effectively in these cells. By 1995, it is expected that at least 50%, and perhaps as much as 90%, of the genetically engineered products for health care will be produced from mammalian cells.

35 The biotechnology market may be segmented in several different ways, the preferred methods are by product source and by stage of the product development cycle. Product source defines the type of cell the protein is isolated from and product development cycle defines whether the product is in the stage of research, development, or manufacturing. The following charts give more information on segmentation and estimates of value-in-use (VIU) and market opportunity for the TCD™ technology. To date, market analysis has been focused on the high value products for health care applications. The segmentation and rest of this discussion focuses on this area.

40 The early phase of product development, research, is done by a large number of highly skilled scientists whose primary objective is the construction and isolation of unique cells with specific properties. Cell growth in research is done on a small scale and lose due to contaminations of a fermentation, although a nuisance, has small economic consequences. However, in the development and manufacturing phases, where the objective is the growth of large quantities of these unique cells, contamination results in a significant economic loss.

45 The following tables compare several important aspects of the termination process and the market opportunity by cell type.

45

50

55

Cell Type	Average Length of Fermentation Cycle	Number of Connections Per Cycle	Relative of Materials	Value Average VIU Per Connection
Bacterial	4 Days	8	1X	\$3
Mammalian	21 Days	60	10X	\$7
Whole Organ	21 Days	42	8X	\$4
<hr/>				
Cell Type	Number of Connections		Market Opportunity	
	1994	2000	1994	2000
Bacterial	5.2MM	7.9MM	\$11MM	\$17MM
Mammalian	3.0MM	8.5MM	\$15MM	\$58MM
Whole Organ	0.5MM	0.8MM	\$ 2MM	\$ 3MM
<b>TOTAL</b>	<b>8.7MM</b>	<b>17.2MM</b>	<b>\$28MM</b>	<b>\$78MM</b>

20

The increase in the number of products in the development and manufacturing phases as well as more products derived from mammalian cells, both with higher VIU's, account for much of the growth in the market opportunity.

The initial targets for the TCD™ are the development and manufacturing phases of mammalian cell culture. The 25 reasons for this choice are:

- significant product loss due to contamination
- high VIU per connection
- very high income potential per TCD™ placement
- rapidly growing segments
- technology still evolving.

30 Our initial TCD™ placements will be with small companies which produce monoclonal antibodies by mammalian cell culture on contract to other companies. These antibodies are used in diagnostic tests and are in clinical studies for disease treatments.

35 Six companies worldwide produce monoclonals on contract which sell for \$2M to \$5M per gram. Their 1990 sales were \$3MM and are forecast to grow to \$8MM (1995) and as high as \$60MM (2000). The demand for monoclonal products exceeds the present capacity of these companies. In addition, at least 20 companies produce monoclonals for their own use. At contract companies, the product loss due to fermentation system contamination is approximately 40 15%/week. Discussions with these companies indicate that most of this contamination appears to occur when entering the system to add fresh nutrients and remove wastes and product (the monoclonals produced by the cells). Presently, there is no simple means to steriley access these fermentation systems.

The strategies for market development in the U.S. are:

- 45 • establish the TCD™ as the state-of-the-art connection technology;
- utilize scientific meetings and seminars to expose TCD™ technology to marketplace;
- initially place the TCD™ in a high value-in-use segment.

Establishing the TCD™ as the standard connection technology for biotechnology depends on demonstrating its 50 effectiveness in reducing contamination. Its convenience and simplicity will also be important. Effectively demonstrating these attributes requires information collected under normal use conditions.

Developing and publishing the experience of TCD™ in cell culture will create the exposure to develop a demand for this technology in the other biotechnology applications and help establish the TCD™ as the state-of-the-art connection technology for this market.

55 In addition to the above described uses of the invention the ionomeric modified poly-ether-ester may also be used in food processing particularly as tubing for fluids and semi-solids and as the material for making sheets and films for bacterial and virus extrusion. When used as sheets or films, the sheet could be draped over the patient and the surgeon would cut through the sheet into the patient. The ionomeric modified poly-ether-ester may in effect be used as a suitable replacement for PVC in virtually all uses of PVC.

It should be noted that the objects and advantages of the invention may be attained by means of any compatible combination(s) particularly pointed out in the items of the following summary of the invention and the appended claims.

**SUMMARY OF THE INVENTION**

5      In an assembly for transferring a fluid between a first location and a remote container by means of plastic tubing, the improvement being in that said plastic tubing is made from an ionomer-modified poly-ether-ester material, said material containing no plasticizer, and said material being capable of being welded to itself to form a seal which resists opening at internal pressure of up to 60 psi, and said seal being capable of opening under external finger pressure.

10     The assembly wherein said material contains from 2% to 15% ionomer.  
The assembly wherein said material contains from 7% to 10% ionomer.  
The assembly wherein said tubing is welded to a polyvinylchloride tube section.  
The assembly wherein assembly is a CAPD assembly.  
The assembly wherein assembly is a urinary drainage assembly.  
15     The assembly wherein assembly is a blood processing assembly.  
The assembly wherein assembly is a chemotherapy assembly.  
The assembly wherein assembly is a parenteral feeding assembly.  
The assembly wherein assembly is a cell culturing assembly.  
The assembly wherein assembly is a food processing assembly.  
20     The assembly wherein said container is made from an ionomer-modified poly-ether-ester material containing from 1% to 50% ionomer.  
In an assembly for transferring a medical fluid from a first location to a remote second location wherein the fluid is in a container at one of the locations and the fluid is conveyed through tubing communicating with the container, the improvement being in that said container is made from an ionomer-modified poly-ether-ester material containing from 25     1% to 50% ionomer.  
The assembly wherein assembly is a CAPD assembly.  
The assembly wherein assembly is a urinary drainage assembly.  
The assembly wherein assembly is a blood processing assembly.  
The assembly wherein assembly is a chemotherapy assembly.  
30     The assembly wherein assembly is a parenteral feeding assembly.  
A plastic tubing for conveying fluid between a first location and a remote container, said tubing being made from an ionomer-modified poly-ether-ester material containing no plasticizer and containing from 2% to 15% ionomer, said tubing being capable of being welded to itself to form a seal which resists opening at internal pressure up to 60 psi, and said seal being capable of being opened under external finger pressure.  
35     In a container for containing medical fluid, the improvement being in that said container is made from an ionomer-modified poly-ether-ester material containing from 1% to 15% ionomer.  
In a method of using a surgical drape during an operation wherein the drape is in sheet form placed over a patient and a surgeon cuts through the sheet during the operation, the improvement being in that the surgical drape is made from an ionomer-modified poly-ether-ester containing from 1% to 50% ionomer.  
40     In a method of conveying medical fluid through plastic tubing from a first location to a second location with the fluid being in a container at one of the locations, the improvement being in that the tubing is made from an ionomer-modified poly-ether-ester containing from 2% to 15% ionomer, and the container being made from an ionomer-modified poly-ether-ester containing from 1% to 50% ionomer.

45     **Claims**

1. In an assembly for transferring a fluid between a first location and a remote container by means of plastic tubing, the improvement being in that said plastic tubing is made from an ionomer-modified poly-ether-ester material, said material containing no plasticizer, and said material being capable of being welded to itself to form a seal which resists opening at internal pressure of up to 60 psi, and said seal being capable of opening under external finger pressure.

50     2. The assembly of Claim 1 wherein said material contains from 2% to 15% ionomer, preferably from 7% to 10% ionomer.

55     3. The assembly of Claim 1 or 2 wherein said tubing is welded to a polyvinylchloride tube section.

4. The assembly of any of Claims 1 to 3 wherein said container is made from an ionomer-modified poly-ether-ester material containing from 1% to 50% ionomer.

5. In an assembly for transferring a medical fluid from a first location to a remote second location wherein the fluid is in a container at one of the locations and the fluid is conveyed through tubing communicating with the container, the improvement being in that said container is made from an ionomeric modified poly-ether-ester material containing from 1% to 50% ionomer.
6. The assembly of any of claims 1 to 3 wherein assembly is: a CAPD assembly;
  - 10 a urinary drainage assembly;
  - a blood processing assembly;
  - a chemotherapy assembly;
  - a parental feeding assembly;
  - a cell culturing assembly; or
  - a food processing assembly.
- 15 7. A plastic tubing for conveying fluid between a first location and a remote container, said tubing being made from an ionomeric modified poly-ether-ester material containing no plasticizer and containing from 2% to 15% ionomer, said tubing being capable of being welded to itself to form a seal which resists opening at internal pressure up to 60 psi, and said seal being capable of being opened under external finger pressure.
- 20 8. In a container for containing medical fluid, the improvement being in that said container is made from an ionomeric modified poly-ether-ester material containing from 1% to 15% ionomer.
9. In a method of using a surgical drape during an operation wherein the drape is in sheet form placed over a patient and a surgeon cuts through the sheet during the operation, the improvement being in that the surgical drape is made from an ionomeric modified poly-ether-ester containing from 1% to 50% ionomer.
- 25 10. In a method of conveying medical fluid through plastic tubing from a first location to a second location with the fluid being in a container at one of the locations, the improvement being in that the tubing is made from an ionomeric modified poly-ether-ester containing from 2% to 15% ionomer, and the container being made from an ionomeric modified poly-ether-ester containing from 1% to 50% ionomer.
- 30

35


40

45

50


55

*Fig.1.*



*Fig.2A.*


*Fig.2.*



*Fig.2B.*


*Fig. 3.*

*E77-200-7-3f PVC*




*Fig. 4.*


*E77-200-7-3*




*Fig.5.(PriorArt)*






*Fig.6.*



*Fig.7.*







European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 95 12 0739

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)						
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim							
E	US-A-5 496 291 (SPENCER DUDLEY W C) 5 March 1996 * the whole document *	1-10	A61L29/00 A61L31/00 C08L67/02						
X	RESEARCH DISCLOSURE, no. 301, May 1989, page 329/330 XP000052490 "BLENDS OF POLYESTER-ETHERS WITH ETHYLENE-ACRYLIC ACID COPOLYMERS" * the whole document *	1-10							
A	US-A-5 089 553 (UMEDA TAKASHI ET AL) 18 February 1992	-----							
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)						
			A61L C08L						
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>6 June 1996</td> <td>Cousins-Van Steen, G</td> </tr> </table>				Place of search	Date of completion of the search	Examiner	THE HAGUE	6 June 1996	Cousins-Van Steen, G
Place of search	Date of completion of the search	Examiner							
THE HAGUE	6 June 1996	Cousins-Van Steen, G							
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document							
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document									